剂量调整EPOCH方案治疗非特指型外周T细胞淋巴瘤疗效评价

Efficacy Evaluation of Dose-adjusted EPOCH Regimen in the Treatment of non-specific Peripheral T-cell Lymphoma

目的对非特指型外周T细胞淋巴瘤的患者给予剂量调整EPOCH方案治疗的临床效果进行分析。方法选取2015年1月～2016年1月南阳市中心医院收治的82例非特指型外周T细胞淋巴瘤的患者进行分析,以随机数字表法将其分为观察组和对照组,观察组给予剂量调整EPOCH方案治疗,对照组给予CHOP方案治疗,对治疗后的临床效果、不良反应进行分析。结果观察组总有效率为97.56%,对照组总有效率为82.92%,差异具有统计学意义(P <0.05);观察组不良反应发生率低于对照组,差异具有统计学意义(P <0.05)。结论非特指型外周T细胞淋巴瘤对患者的影响较大,在临床治疗中给予剂量调整EPOCH方案治疗效果较好,并且不良反应较少,值得临床应用。

Objective To analyze the clinical effect of dose-adjusted EPOCH regimen in patients with non-specific peripheral T-cell lymphoma. Methods Eighty-two patients with non-specific peripheral T-cell lymphoma admitted to Nanyang Central Hospital from January 2015 to January 2016 were enrolled. The patients were randomly divided into observation and control groups through random digital table method. The dose-adjusted EPOCH regimen was given to patients in the observation group, while patients in the control group were treated with CHOP regimen. The clinical effects and adverse reactions after treatment were analyzed. Results The total effective rate was 97.56% in the observation group and 82.92% in the control group. The difference was statistically significant（P〈0.05）. The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant（P〈0.05）. Conclusion Non-specific peripheral T-cell lymphoma has bad effects on patients. The dose-adjusted EPOCH regimen is better in clinical treatment, and the adverse reactions are less, which is worthy of clinical application.